Balancing ACT: evaluating the effectiveness of psychoeducation and acceptance and commitment therapy (ACT) groups for people with bipolar disorder

Balancing ACT: evaluating the effectiveness of psychoeducation and acceptance and commitment therapy (ACT) groups for people with bipolar disorder: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN73327972

Enrollment

Registered

2017-03-27

Start date

2017-05-01

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis with bipolar disorder/symptoms Mental and Behavioural Disorders

Interventions

After agreeing to take part, participants will complete questionnaires about how they are feeling, what they are doing, and recent treatment they have received. Participants will be randomised through

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Treated under Lambeth or Southwark Promoting Recovery Services 2. Diagnosis/symptoms of Bipolar Disorder 3. Available for the study duration 4. Sufficient English language ability to be able to complete assessment measures and therapy, without interpreter support (as this is not feasible in a group intervention). 5. Aged 18 years and over

Exclusion criteria

Exclusion criteria: 1. Inability to remain in a group setting, attend, understand and interact for up to 2 hours 2. Participants who are unable to consent for themselves (i.e. who lack capacity)

Design outcomes

Primary

Measure	Time frame
Psychological wellbeing, assessed using the Brief Quality of Life in Bipolar Disorder (Brief QoL.BD) at 10 weeks	—

Secondary

Measure	Time frame
1. Mental health relapses, measured by service use as an average per month for the 12 months preceding baseline and the 3 months post-baseline (during the trial) 2. Psychological wellbeing, assessed by the Brief QoL BD at 14 weeks 3. Mood, assessed using a bespoke Mood Monitoring Measure (MMM) and the Internal States Scale (ISS) 4. Distress, assessed using the Clinical Outcomes in Routine Evaluation Measure (CORE-10) 5. Recovery, assessed using the Bipolar Recovery Questionnaire (BRQ) 6. Psychological processes of change, assessed using the Valuing Questionnaire (VQ8); the Acceptance and Action Questionnaire-II (AAQ-II); and the Southampton Mindfulness Questionnaire (SMQ) Assessed at baseline, 10 and 14 weeks	—

Measure

Time frame

1. Mental health relapses, measured by service use as an average per month for the 12 months preceding baseline and the 3 months post-baseline (during the trial) 2. Psychological wellbeing, assessed by the Brief QoL BD at 14 weeks 3. Mood, assessed using a bespoke Mood Monitoring Measure (MMM) and the Internal States Scale (ISS) 4. Distress, assessed using the Clinical Outcomes in Routine Evaluation Measure (CORE-10) 5. Recovery, assessed using the Bipolar Recovery Questionnaire (BRQ) 6. Psychological processes of change, assessed using the Valuing Questionnaire (VQ8); the Acceptance and Action Questionnaire-II (AAQ-II); and the Southampton Mindfulness Questionnaire (SMQ) Assessed at baseline, 10 and 14 weeks

—

Countries

United Kingdom

Contacts

Public ContactEmma O'Donoghue

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 5, 2026